Pharma Resources (Shanghai) Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. was established in 2007 and is a one-stop comprehensive service provider for the research and commercial production of small molecule innovative drugs. We are committed to drug discovery, research and development of pharmaceutical processes, and commercial production of raw materials and intermediates. Hongbo Pharmaceutical's new drug research and development services cover the entire process of preclinical new drug research, mainly including drug discovery and process research and development. In terms of drug discovery, Hongbo assists clients in designing, screening, and optimizing candidate and lead compounds, as well as conducting structural improvements and preliminary safety screening to obtain compounds with intellectual property rights and excellent pharmacological effects. In terms of process research and development, Hongbo provides new drug process chemistry services and innovative synthesis processes to global pharmaceutical companies, helping customers achieve commercial production of intermediates and raw materials from kilogram to ton scales, with the goal of low cost, safety, environmental protection, and reliability. With its advantages in pharmaceutical process technology, Hongbo also provides customized production services for key intermediates of new drugs, as well as research and production of characteristic raw material drug intermediates with complex chemical structures and high synthesis difficulties. In March 2021, Hongbo Pharmaceutical successfully submitted its IPO application on the Shenzhen Stock Exchange's ChiNext board and passed the review of the Shenzhen Stock Exchange Listing Committee in April 2022. On July 8, 2022, the China Securities Regulatory Commission approved the application of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. for its initial public offering of shares and listing on the Shenzhen Growth Enterprise Market. On October 18, 2022, Hongbo Pharmaceutical successfully issued 19.25 million A-shares and was listed on the ChiNext. Hongbo Pharmaceutical adheres to its core values: "Science first, continuous innovation". Always pursuing scientific excellence and technological innovation, regardless of how the internal and external environment changes, this pursuit enables Hongbo to meet the constantly changing needs of customers and the market, and ensure continuous competitiveness to maintain the sustainable development of the enterprise. |
| Headquarter | Shanghai |
| Establish Date | 12/14/2007 |
| Listed Code | 301230.SZ |
| Listed Date | 11/1/2022 |
| Chairman | PING CHEN |
| CEO | PING CHEN |
| Website | www.pharmaresources.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
